NIT is currently conducting multiple clinical trials of NT-I7 as a monotherapy and in combination with leading immunotherapeutics such as checkpoint inhibitors, cancer vaccines, and more.

In addition, NIT is relentlessly conducting proof-of-concept animal studies in additional indications to further strengthen our pipeline and broaden the proof of applicability of NT-I7.

NT-I7 (efineptakin alfa, rhIL-7-hyFc)

Development Stage
Preclinical Phase 1 Phase 2 Phase 3
Monotherapy Single Dose – Glioblastoma (GBM) Ph1/pilot Learn more about the clinical trial
Multiple Doses1 – Glioblastoma (GBM) Ph1/2 Learn more about the clinical trial
SCCHN Window-of-Opportunity w/Salvage Surgery1 Ph1
Checkpoint Inhibitor Combinations * Pembrolizumab2 - Triple Negative Breast Cancer (TNBC) Ph1b/2a Learn more about the clinical trial
Pembrolizumab3 – Solid Tumors (TNBC, NSCLC, SCLC, PanCA, MSS-CRC) Ph1b/2a Learn more about the clinical trial
Atezolizumab4 - High Risk Skin Cancers (MCC, cSCC, Melanoma) Ph1b/2a Learn more about the clinical trial
Nivolumab5 – Gastric, GEJ, and Esophageal Adenocarcinomas Ph2
CAR-T Combinations  
Monotherapy Adjuvant with Vaccines - Elderly Cancer Survivors Ph1/1b¹ Learn more about the clinical trial
COVID-19 - Randomized, Double-Blind, PBO-Controlled Ph1
COVID-191 - Randomized, Double-Blind, PBO-Controlled Ph1
Progressive Multifocal Leukoencephalopathy1,6
Idiopathic CD4 Lymphocytopenia1,7
Monotherapy Acute Radiation Syndrome
1. Investigator-initiated trial
2. Clinical Trial Collaboration with Genexine and Merck
3. Clinical Trial Collaboration with Merck
5. Clinical Trial Collaboration with BMS
6. Orphan Drug Designation in US (June 2020)
7. Orphan Drug Designation in EU (May 2017) and US (April 2019)